Takeda has decided that there is a future for its aurora kinase A inhibitor alisertib after it failed a phase 3 trial in lymphoma – but the company won't be taking the drug forward itself. Enter ...

A pioneering clinical trial backed by the EU and drugmaker Takeda will look for biomarkers that could be used to identify people at risk of developing Crohn's disease in the hope of intervening ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

KUSATSU, Gunma Prefecture--An assemblywoman here who accused the town mayor of sexual assault lost her seat after more than 90 percent of voters called for her dismissal in a Dec. 6 recall election.

3382.T Seven & i Holdings Co., Ltd.